Orexo
14,2
SEK
-0,28 %
Mindre end 1K følgere
ORX
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
-0,28%
-7,67%
-25,18%
-18,86%
+30,76%
-16,47%
-25,26%
-78,12%
-84,21%
Orexo is a Swedish pharmaceutical company that develops medicines based on proprietary formulation technologies that meet major medical needs. In the US market, Orexo offers treatment solutions for patients suffering from opioid addiction and related diseases. Products targeting other therapeutic areas are developed and commercialized worldwide in collaboration with partners. The head office, where the research and development work is conducted, is located in Uppsala.
Læs mereMarkedsværdi
492,89 mio. SEK
Aktieomsætning
67,23 t SEK
Omsætning
590 mio.
EBIT %
-23,78 %
P/E
-
Udbytteafkast, %
-
Finanskalender
6.5
2025
Delårsrapport Q1'25
8.5
2025
Generalforsamling '25
16.7
2025
Delårsrapport Q2'25
Alle
Selskabspræsentationer
Selskabsmeddelelser
Eksterne analyser
ViserAlle indholdstyper
Invitation to presentation of Orexo´s Q1 2025 Interim Report
Press release
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools

Orexo, Audiocast with teleconference, Q1'25
Notice of Annual General Meeting of Orexo
Orexo publishes the Annual and Sustainability Report for 2024
Carnegie Access: Orexo: Highlights from Carnegie’s Healthcare Conference
Carnegie Access: Orexo: Stability without growth – Q4(24) review
